Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Sponsor: Cytrellis Biosystems, Inc.
Summary
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity
Official title: Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series
Key Details
Gender
All
Age Range
30 Years - 65 Years
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2025-10-14
Completion Date
2026-02-28
Last Updated
2025-12-31
Healthy Volunteers
No
Conditions
Interventions
ellacor
dermal non-thermal micro-coring device
Locations (1)
Tri Valley Plastic Surgery
Dublin, California, United States